SEC Form 4 · accession 0001127602-17-032257
HAEMONETICS CORP · HAE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dan Goldstein
Officer — Chief Accounting Officer
Period of report
Oct 25, 2016
Accepted (ET)
Nov 15, 2017 · 6:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000313143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 25, 2016 | A | 1,350 | $0.00 | A | 3,747 | D | |
| Common StockF1 | Jun 6, 2017 | A | 1,080 | $0.00 | A | 4,827 | D | |
| Common Stock | Nov 13, 2017 | M | 2,607 | $34.42 | A | 7,434 | D | |
| Common Stock | Nov 13, 2017 | M | 1,456 | $34.21 | A | 8,890 | D | |
| Common Stock | Nov 13, 2017 | S | 2,607 | $54.945 | D | 6,283 | D | |
| Common Stock | Nov 13, 2017 | S | 300 | $54.921 | D | 5,983 | D | |
| Common Stock | Nov 13, 2017 | S | 200 | $54.94 | D | 5,783 | D | |
| Common Stock | Nov 13, 2017 | S | 956 | $54.957 | D | 4,827 | D | |
| Common Stock | Nov 13, 2017 | S | 560 | $54.841 | D | 4,267 | D | |
| Common Stock | Nov 13, 2017 | S | 68 | $54.886 | D | 4,199 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F2 | $34.21 | Oct 25, 2016 | A | 5,826 | A | Oct 25, 2017 | Oct 25, 2023 | Common Stock | 5,826 | 5,826 | D |
| Non-qualified Stock Option (Right to Buy)F2 | $41.64 | Jun 6, 2017 | A | 4,426 | A | Jun 6, 2018 | Jun 6, 2024 | Common Stock | 4,426 | 4,426 | D |
| Non-qualified Stock Option (Right to Buy) | $34.42 | Nov 13, 2017 | M | 2,607 | D | Apr 6, 2017 | Apr 6, 2023 | Common Stock | 2,607 | 7,821 | D |
| Non-qualified Stock Option (Right to Buy) | $34.21 | Nov 13, 2017 | M | 1,456 | D | Oct 25, 2017 | Oct 25, 2023 | Common Stock | 1,456 | 4,370 | D |
Explanation of responses
- F1Restricted Stock Units which vest 25% per year over 4 years following the grant date.
- F2Non-qualified stock option grant providing a right to buy shares of common stock exercisable in annual increments of 25% beginning on the first anniversary of the date of grant.